Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Natera, Inc.
  6. Summary
    NTRA   US6323071042

NATERA, INC.

(NTRA)
  Report
Delayed Nasdaq  -  04:00 2022-07-05 pm EDT
38.79 USD   +5.04%
06/29Natera Says Study Validates Performance of Its Prospera Transplant Rejection Test
MT
06/29Trifecta Study Establishes New Validation Standard for dd-cfDNA in Kidney Transplant Rejection With Largest Prospective, Multisite, Fully Biopsy-Matched Study
PR
06/14TRANSCRIPT : Natera, Inc. Presents at Goldman Sachs 43rd Annual Global Healthcare Conference, Jun-14-2022 10:00 AM
CI
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/28/2022 06/29/2022 06/30/2022 07/01/2022 07/05/2022 Date
37.72(c) 36.87(c) 35.44(c) 36.93(c) 38.79(c) Last
872 238 1 305 973 1 039 602 743 924 819 840 Volume
-5.01% -2.25% -3.88% +4.20% +5.04% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 805 M - -
Net income 2022 -573 M - -
Net cash position 2022 60,5 M - -
P/E ratio 2022 -6,58x
Yield 2022 -
Sales 2023 1 002 M - -
Net income 2023 -513 M - -
Net Debt 2023 121 M - -
P/E ratio 2023 -7,66x
Yield 2023 -
Capitalization 3 736 M 3 736 M -
EV / Sales 2022 4,56x
EV / Sales 2023 3,85x
Nbr of Employees 2 670
Free-Float 96,0%
More Financials
Company
Natera, Inc. is a diagnostics company that is focused on the development and commercialization of molecular testing services, applying its technology in the fields of women’s health, oncology and organ health. The Company’s cell-free deoxyribonucleic acid (DNA) or (cfDNA) technology combines its molecular assays, which reliably measure many informative regions across the genome from samples as small as a single... 
Read more
More about the company
Ratings of Natera, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
D
More Ratings
All news about NATERA, INC.
06/29Natera Says Study Validates Performance of Its Prospera Transplant Rejection Test
MT
06/29Trifecta Study Establishes New Validation Standard for dd-cfDNA in Kidney Transplant Re..
PR
06/14TRANSCRIPT : Natera, Inc. Presents at Goldman Sachs 43rd Annual Global Healthcare Conferen..
CI
06/09NATERA : 2022 Proxy Statement
PU
06/01NATERA, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
05/31Natera to Present New Signatera™ Clinical Data Across Multiple Cancer Types at th..
PR
05/26NATERA, INC. COMPANY NEWS : Berger Montague Investigates Securities Fraud Allegations Agai..
PR
05/24Natera Appoints Minetta Liu, M.D. as Chief Medical Officer of Oncology
PR
05/24Natera, Inc. Announces Executive Changes
CI
05/16Matthew Rabinowitz, Natera Co-Founder and Executive Chairman of the Board, Makes Additi..
PR
05/16Piper Sandler Adjusts Natera's Price Target to $60 From $75, Reiterates Overweight Rati..
MT
05/09JPMorgan Adjusts Price Target for Natera to $80 From $150, Maintains Overweight Rating
MT
05/09Morgan Stanley Lowers Natera's Price Target to $70 From $110, Maintains Overweight Rati..
MT
05/06NATERA, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS ..
AQ
05/05NATERA : Q1 Earnings Snapshot
AQ
More news
News in other languages on NATERA, INC.
06/29Natera affirme que l'étude valide la performance de son test de rejet de greffe Prosper..
05/24Natera, Inc. annonce des changements de direction
05/05La perte de Natera au premier trimestre se creuse alors que le chiffre d'affaires augme..
05/05Earnings Flash (NTRA) NATERA affiche un chiffre d'affaires de 194,1 millions de dollars..
05/05Natera, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2022
More news
Analyst Recommendations on NATERA, INC.
More recommendations
Chart NATERA, INC.
Duration : Period :
Natera, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NATERA, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 12
Last Close Price 38,79 $
Average target price 84,73 $
Spread / Average Target 118%
EPS Revisions
Managers and Directors
Stephen Chapman Chief Commercial Officer
Michael Burkes Brophy VP-Corporate Development & Investor Relations
Matthew Rabinowitz President, Chief Executive Officer & Director
Eric A. Evans Chief Scientific Officer
Rishi Kacker Chief Technology Officer
Sector and Competitors
1st jan.Capi. (M$)
NATERA, INC.-58.46%3 736
BIOMÉRIEUX-21.10%11 937
DIASORIN S.P.A.-21.11%7 342
10X GENOMICS, INC.-66.44%5 667
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.3.27%5 322
LANTHEUS HOLDINGS, INC.124.06%4 443